IBI-3055

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug NameIBI-3055

Drug Alias NameIBI-3055IBI3055

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD19Anti-BCMAAnti-CD3

TargetsB-lymphocyte antigen CD19B-cell maturation proteinT cell surface glycoprotein CD3

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesInnovent Biologics Inc

China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A